Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Inovio to participate at Marcum Microcap Conference, BIO International Convention

Inovio to participate at Marcum Microcap Conference, BIO International Convention

Study shows increase in medical imaging in health maintenance organization systems

Study shows increase in medical imaging in health maintenance organization systems

Researchers identify prognostic marker in chronic lymphocytic leukemia

Researchers identify prognostic marker in chronic lymphocytic leukemia

Normal p53 gene makes breast cancer chemotherapy with doxorubicin less effective

Normal p53 gene makes breast cancer chemotherapy with doxorubicin less effective

Study shows how ruthenium-based drugs may be more effective at fighting cancer cells

Study shows how ruthenium-based drugs may be more effective at fighting cancer cells

Accumulated CT radiation dose triples pediatric cancer risk

Accumulated CT radiation dose triples pediatric cancer risk

Diabetes linked to increased blood cancer risk

Diabetes linked to increased blood cancer risk

Distinct cancer 'signatures' may help predict response to estrogen-lowering therapy

Distinct cancer 'signatures' may help predict response to estrogen-lowering therapy

Strand, Trovagene enter MOU to license and validate HPV assay technology

Strand, Trovagene enter MOU to license and validate HPV assay technology

IRCM researchers make important breakthrough in the field of immunology

IRCM researchers make important breakthrough in the field of immunology

Risk of leukaemia and brain cancer in children could be tripled by radiation exposure from CT scans

Risk of leukaemia and brain cancer in children could be tripled by radiation exposure from CT scans

Patients with type 2 diabetes have 20% increased risk of blood cancers

Patients with type 2 diabetes have 20% increased risk of blood cancers

Cardio-protective drug during cancer treatment may prevent heart damage in children

Cardio-protective drug during cancer treatment may prevent heart damage in children

New PD-1 blocking antibody shows promise against advanced kidney cancer

New PD-1 blocking antibody shows promise against advanced kidney cancer

Updated results from three trials of Bruton's ibrutinib for treatment of CLL/SLL

Updated results from three trials of Bruton's ibrutinib for treatment of CLL/SLL

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

New data from ImmunoGen’s SAR3419 Phase I study on CD19+ NHL

New data from ImmunoGen’s SAR3419 Phase I study on CD19+ NHL

CTI acquires world-wide rights to S*BIO’s pacritinib

CTI acquires world-wide rights to S*BIO’s pacritinib

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.